mRNA 疫苗开发用于 COVID-19 的观点和展望。
Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
机构信息
Pediatric Heart Center, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
出版信息
Curr Med Chem. 2022;29(23):3991-3996. doi: 10.2174/0929867329666220216110931.
BACKGROUND
The current coronavirus disease 2019 (COVID-19) pandemic, since first reported in Wuhan, has inspired worldwide efforts to develop effective COVID-19 vaccination strategies. mRNA vaccines encoding COVID-19 antigens have emerged prominantlyin this global race due to their high effectiveness and simple manufacturing process. Notably, two COVID-19 mRNA vaccines, mRNA-1273 and BNT162b2, have survived in clinical trials and been authorized for emergency use across variouscountries.
SUMMARY
Recent advances on mRNA vaccine development for COVID-19 are discussed in this perspective, including sequence design, chemical modification, manufacturing process, and in vivo delivery. Phase I to IV clinical trials of mRNA-1273 and BNT162b2 are then summarized, respectively.
CONCLUSION
Using mRNA vaccines is a promising strategy to achieve mass vaccination in the COVID-19 pandemic. We hope that future studies of mRNA vaccine technology will overcome existing limitations and help people cope with COVID-19.
背景
自武汉首次报告以来，当前的 2019 年冠状病毒病（COVID-19）大流行激发了全球努力开发有效的 COVID-19 疫苗接种策略。由于其高效性和简单的制造工艺，编码 COVID-19 抗原的 mRNA 疫苗在这场全球竞赛中脱颖而出。值得注意的是，两种 COVID-19 mRNA 疫苗，mRNA-1273 和 BNT162b2，在临床试验中幸存下来，并在不同国家获得紧急使用授权。
摘要
本观点讨论了针对 COVID-19 的 mRNA 疫苗开发的最新进展，包括序列设计、化学修饰、制造工艺和体内传递。然后分别总结了 mRNA-1273 和 BNT162b2 的 I 期至 IV 期临床试验。
结论
使用 mRNA 疫苗是在 COVID-19 大流行中实现大规模疫苗接种的有前途的策略。我们希望未来对 mRNA 疫苗技术的研究将克服现有局限性，帮助人们应对 COVID-19。
Zotero 插件